Agios Pharmaceuticals (NASDAQ:AGIO) Reaches New 12-Month High – Should You Buy?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reached a new 52-week high during trading on Thursday . The stock traded as high as $53.81 and last traded at $53.60, with a volume of 569806 shares. The stock had previously closed at $51.59.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AGIO. Scotiabank raised their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Finally, Raymond James reiterated an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $52.33.

Agios Pharmaceuticals Trading Up 7.2 %

The company’s 50 day simple moving average is $45.15 and its 200 day simple moving average is $42.90. The stock has a market capitalization of $3.37 billion, a PE ratio of 5.20, a PEG ratio of 0.47 and a beta of 0.75.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.93% of the stock is owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the second quarter valued at $37,000. Quest Partners LLC purchased a new stake in shares of Agios Pharmaceuticals during the second quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares in the last quarter. CWM LLC grew its stake in shares of Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 1,836 shares in the last quarter. Finally, North Star Asset Management Inc. acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at $216,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.